Shinabarger D, Zurenko GE, Hesje CK, Sanfilippo CM, Morris TW, Haas W.  2011. 
Evaluation of the effect of bacterial efflux pumps on the antibacterial activity of the 
novel fluoroquinolone besifloxacin.  J. Chemother.  23:80-86.

Butler MM, Williams JD, Peet NP, Moir DT, Panchal RG, Bavari S, Shinabarger DL, 
Bowlin TL.  2010.  Comparative in vitro activity profiles of novel bis-indole antibacterials 
against gram-positive and gram-negative clinical isolates.  Antimicrob. Agents Chemother.  54:3974-3977.

Sweeney M, Watts J, Portis E, Lucas M, Nutsch R, Meeuwse D, Bade D, Oliver V, Morck DW,
Shinabarger D, Poppe S, Peterson M, Sweeney D, Knechtel M, Zurenko G.  2010.  
Identification of Porphyromonas levii isolated from clinical cases of bovine interdigital necrobacillosis 
by 16S rRNA sequencing.  Vet. Ther. 10: E1 – E10.

Schaadt R, Sweeney D, Shinabarger D, Zurenko G.  2009.   In vitro activity of TR-700, the active ingredient 
of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob. Agents 
Chemother. 53:3236-3239.         

Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D,  Zurenko G. 2008. 
In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.  
Antimicrob. Agents Chemother. 52:4442-4447. 

Tenover FC, Williams PP, Stocker S, Thompson A, Clark LA, Limbago B, Carey RB, Poppe SM, Shinabarger D, 
McGowan JE Jr.  2007.  Accuracy of six antimicrobial susceptibility methods for testing linezolid against Staphylococci 
and Enterococci.  J. Clin. Microbiol. 45:2917-2922.

Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, 
Xiong L, Mankin AS. 2007.  The site of action of oxazolidinone antibiotics in living bacteria and in human 
mitochondria. Mol Cell. 26:393-402. 

Swaney S, McCroskey M, Shinabarger D, Wang Z, Turner BA, Parker CN. 2006.  
Characterization of a high-throughput screening assay for inhibitors of elongation factor P and ribosomal 
peptidyl transferase activity. J Biomol Screen. 11:736-42.

Xu J, Golshani A, Aoki H, Remme J, Chosay J, Shinabarger DL, Ganoza MC.  2005. Protected nucleotide 
G2608 in 23S rRNA confers resistance to oxazolidinones in E. coli. Biochem Biophys Res Commun. 328:471-476.

Colca JR, McDonald WG, Waldon DJ, Thomasco LM, Gadwood RC, Lund ET, Cavey GS, Mathews WR, Adams LD, 
Cecil ET, Pearson JD, Bock JH, Mott JE, Shinabarger DL, Xiong L, Mankin AS . 2003. 
Crosslinking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem. 278:21972-21979. 

Polacek N, Swaney S, Shinabarger D, Mankin AS. 2002. SPARK-A Novel Method To Monitor Ribosomal Peptidyl 
Transferase Activity. Biochemistry. 41 :11602-10. 

Aoki H, Ke L, Poppe SM, Poel TJ, Weaver EA, Gadwood RC, Thomas RC, Shinabarger DL, Ganoza MC. 2002. 
Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob. Agents Chemother. 
46 :1080-1085. 

Zurenko GE, JK Gibson, DL Shinabarger , PA Aristoff, CW Ford, and WG Tarpley . 
Oxazolidinones: A New Class of Antibacterials. Current Opinion in Pharmacology. 2001, 1:470-476. 

Zhou CC, Swaney SM, Shinabarger DL, Stockman BJ. 2002. 
1 H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob. 
Agents Chemother. 46 :625-9. 

Kiriukhin, M.Y., D.V. Debabov, D.L. Shinabarger, and F.C. Neuhaus. 2001. 
Biosynthesis of the glycolipid anchor in lipoteichoic acid of Staphylococcus aureus 
RN4220: role of YpfP, the diglucosyldiacylglycerol synthase. J. Bacteriol. 183:3506-3514. 

Prystowsky, J., F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin. 2001. 
Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in 
vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2154-2156. 

Xiong, L., P. Kloss, S. Douthwaite, N. Møller Andersen, S. Swaney, D.L. Shinabarger, and A. S. Mankin. 2000. 
Oxazolidinone resistance mutations in 23S ribosomal RNA of Escherichia coli reveal the central region of 
domain V as the primary site of the drug action. J. Bacteriol. 182:5325-5331. 

Gadwood, R.C., and D. Shinabarger. 2000. Progress in the oxazolidinone antibacterials. 
Ann. Rep. Med. Chem. 35:135-144. 

Shinabarger D. 1999. Mechanism of action of the oxazolidinone antibacterial agents. 
Exp. Opin. Invest. Drugs. 8:1195-1202. 

Kloss, P., L. Xiong, D. L. Shinabarger, and A. S. Mankin. 1999. 
Resistance mutations in 23S rRNA identify the site of action of protein synthesis inhibitor, 
linezolid, in the ribosomal peptidyl transferase center. J. Mol. Biol. 294:93-101. 

Swaney SM, H Aoki, MC Ganoza, and DL Shinabarger. 1998. 
The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob.
Agents Chemother. 42:3251-3255. 

Shinabarger, D.L., K.R. Marotti, R.W. Murray, A.H. Lin, E.P. Melchior, S.M. Swaney, D.S. Dunyak, W.F. Demyan, 
and J.M. Buysse. 1996. 
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. 
Antimicrob. Agents Chemother. 41:2132-2136. 

Parsek, M.P., S.M. McFall, D.L. Shinabarger, and A.M. Chakrabarty. 1994. 
Interaction of two LysR-type regulatory proteins CatR and ClcR with heterologous promoters: 
Functional and evolutionary implications. Proc. Natl. Acad. Sci. 91: 12393-12397. 

May. T.B., D. Shinabarger, A. Boyd, and A.M. Chakrabarty. 1993. 
Identification of amino acid residues involved in the activity of phosphomannose isomerase-guanosine 
5'-diphospho-D-mannose pyrophosphorylase. 1994. J. Biol. Chem. 269:4872-4877. 

Shinabarger, D., T.B. May, A. Boyd, M. Ghosh, and A.M. Chakrabarty. 1993. 
Nucleotide sequence and expression of the Pseudomonas aeruginosa alg F gene controlling the 
acetylation of alginate. Mol. Microbiol. 9:1027-1035. 

Boyd, A., M. Ghosh, T.B. May, D. Shinabarger, R. Keogh, and A.M. Chakrabarty. 1993. 
Sequence of the alg L gene of Pseudomonas aeruginosa and purification of its alginate lyase product. 
Gene. 131:1-8. 

Parsek MR, Shinabarger DL, Rothmel RK, Chakrabarty AM. 1992. 
Roles of CatR and cis,cis-muconate in activation of the catBC operon, which is involved in benzoate 
degradation in Pseudomonas putida. J. Bacteriol. 4:7798-7806. 

Rothmel RK, Shinabarger DL, Parsek MR, Aldrich TL, Chakrabarty AM. 1991. 
Functional analysis of the Pseudomonas putida regulatory protein CatR: transcriptional studies and 
determination of the CatR DNA-binding site by hydroxyl-radical footprinting.J. Bacteriol.173:4717-4724. 

May TB, Shinabarger D, Maharaj R, Kato J, Chu L, DeVault JD, Roychoudhury S, Zielinski NA, Berry A, 
Rothmel RK, Chakrabarty, AM. 1991. 
Alginate synthesis by Pseudomonas aeruginosa : a key pathogenic factor in chronic pulmonary infections of 
cystic fibrosis patients. Clin Microbiol Rev. 4:191-206. 

Roychoudhury S, Zielinski NA, DeVault JD, Kato J, Shinabarger DL, May TB, Maharaj R, Kimbara K, Misra TK, 
Chakrabarty AM. 1991. 
Pseudomonas aeruginosa infection in cystic fibrosis: biosynthesis of alginate as a virulence factor. 
Antibiot. Chemother. 44:63-67. 

Shinabarger, D.L., A. Berry, T.B. May, R. Rothmel, A. Fialho, and A.M. Chakrabarty. 1991. 
Purification and characterization of phosphomannose isomerase-guanosine diphospho-D-mannose 
pyrophosphorylase. J. Biol. Chem. 266:2080-2088. 

Shinabarger, D.L., G.A. Keesler, and L.W. Parks . 1989. 
Regulation by heme of sterol uptake in Saccharomyces cerevisiae . Steroids. 53:607-623. 

Shinabarger, D.L., and H.D. Braymer. 1986. 
Glyphosate catabolism by Pseudomonas sp. Strain PG2982. J. Bacteriol. 168:702-707.